Oser Communications Group

NACDS.TSE19.Aug25

Issue link: http://osercommunicationsgroup.uberflip.com/i/1153031

Contents of this Issue

Navigation

Page 18 of 55

Chain Drugstore Daily 1 9 Sunday, August 25, 2019 Mobile Spaces from Uniweb "Take it to go" with Uniweb's product line for mobile health centers, disaster response units, on-site office space or roving training facilities. Take your oper- ation on the road by installing Uniweb products in trailers, buses, box trucks and cargo containers to create a space where medical staff can work on the vehicle in exam areas, office areas and labs. Keep supplies, tools and equipment secured and organized using Uniweb's 24-gauge steel panels, workstations, locking cabi- nets and accessories. C2 cabinets, five- drawer cabinets, two-drawer cabinet, under counter drawers and Lok 'n Roll are just a few of the company's secure and elite locking units. Storage Space Need extra storage in such a tight area? Need to secure merchandise or files? The Lok 'n Roll Cabinet ® does both! It pro- vides a secure, locking cabinet with a Uniweb shape exterior and a sliding bay pull-out housed within. Stock supplies inside and out! In a health mobile, this cabinet can be used for C2 narcotics lock up, HIPAA regulated patient records and CAL file storage, will call, etc. Add a sliding wall unit to increase storage capacity without increasing the overall footprint. Double, even triple the storage of your wall panel. Uniweb's wall panel is secured to the interior wall, a track is laid down in front of the panel, then a second complete gliding panel or bay is assembled in front. Work Space Need ample work surfaces? The Uniweb workstation is a true multifunctional system that can be custom-built to serve a variety of needs. Featuring storage areas both above and below the counter translates into a roomy and uncluttered work- space. The convenient modular wiring system means your worksta- tion will be up and run- ning in no time. The system's efficiency is complemented by the aesthetic appeal of lam- inated counter tops, as well a wide range of color choices, locking drawer and cabinet abilities, and privacy screen options. Furthermore, the adjustable height powered workstation allows for a smooth powered transition from sitting to stand- ing positions and everything in between with five preset height settings that adjust from 24 inches to 51 inches at the touch of a button. This sleek furniture hides bulky wires and connections. The back- splash options allow an extensive selec- tion of workflow accessories available, all designed to your color specification. Private Space Need partitions within your space for one-on-one customer care? Maintain privacy with the use of Uniweb's consultation/immuniza- tion pop-out screens which provide convenience with their portable and flexible ADA compliant design. Uniweb crafts a welcoming and comfort-focused ambiance with the use of privacy glass doors and pan- els and natural light to keep the room comfortable. Combine this with sound absorbing décor fabric or wood panels to manage patient confidentiality. These dynamic pop-out rooms provide unsur- passed utility at an affordable price. Give Uniweb your challenges today. For over 26 years, Uniweb has been a proud member of NACDS. Visit Uniweb at booth #2231. For more information, call 800.486.4932 or go to www.uniwebinc.com. Delivering Success: Amneal Posts Impressive Stats Amneal set new company records in 2018, closing out the year as the leader in U.S. generic approvals and launches with 62 final and 10 tentative ANDA approvals plus 42 product launches. The company celebrated the accomplishment as a bright spot in a challenging generics market rife with increased competition and intense pricing pressures. "We achieved industry-leading pipeline execution in 2018 with a consis- tent pace of new approvals and launch- es," notes Andy Boyer, Executive Vice President, Commercial Operations at Amneal. "We are positioned to launch up to 50 in 2019." Notable 2018 launches included Methylphenidate Hydrochloride extend- ed release tablets, Phytonadione tablets, Levothyroxine tablets, Potassium Chloride oral solution, Erythromycin instant release tablets and Colesevelam Hydrochloride tablets. The company has already launched more than 20 products in 2019, including its first two transder- mal system products (rivastigmine and estradiol) along with testosterone gel and bosentan tablets. Focusing Generic R&D Efforts on Complex, High-Value Products To help better insulate the company from market competition and pricing chal- lenges, Amneal continues to focus aggressively on building a diversified pipeline of complex, high-value prod- ucts. Its Generics R&D team successfully filed 31 ANDAs in 2018, 65 percent of which were non-oral solid products, cre- ating a pipeline of 105 filings across var- ious dosage forms. Additionally, Amneal currently has nearly 100 generic products in development, almost a quarter of which are injectables, a segment the company has increasingly tar- geted in 2019 and beyond. Specialty Pharma Business Highlights Amneal is also focused on strengthening specialty pharma, which diversifies its business beyond generics. The company recently provided updates regarding ongoing development work on investigational drug IPX203, its extended release formulation of car- bidopa-levodopa for patients with advanced Parkinson's disease. Top line results are expected in the first half of 2020, with a New Drug Application (NDA) filing expected in 2021. Integration Highlights Amneal exceeded its 2018 integration synergy target, capturing $60 million in cost savings. Other key highlights includ- ed the harmonization of its Order-to- Cash system/processes, consolidating all distribution within its Glasgow, Kentucky operations, and the rebranding of its Impax Specialty and Gemini busi- nesses to Amneal Specialty. With integration now complete, Amneal has shifted its focus to optimizing and strength- ening the company's infrastructure and systems, generating additional cost-savings that will help Amneal be even more competitive. "2018 was marked by several key strategic milestones, most notably the reshaping of our company through the merger of Impax and Amneal," says Boyer. "By the end of the year, we com- pleted the integration of the two companies and accelerated the capture of synergies, resulting in approximately $60 million of cost savings for the year. We also strategi- cally deployed capital with the acquisition of Gemini Laboratories and through sever- al partnerships including agreements with Jerome Stevens Pharmaceuticals, Inc. and Lannett for Levothyroxine." Visit Amneal at booth #201. For more information, go to www.amneal.com.

Articles in this issue

Links on this page

view archives of Oser Communications Group - NACDS.TSE19.Aug25